OPTIBIOTIX HEALTH PLC |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.42 GBX | -1.86% |
|
-1.86% | -34.88% |
| 25/03 | OptiBiotix Health raises GBP1.4 million to invest in "driving sales" | AN |
| 25/03 | OptiBiotix Health Raises GBP1.4 Million via Share Placing, Subscription | MT |
| Sales 2021 | 2.21M 2.77M 231M | Sales 2022 | 457K 573K 47.77M | Capitalization | 12.08M 15.14M 1.26B |
|---|---|---|---|---|---|
| Net income 2021 | 6M 7.52M 627M | Net income 2022 | 2M 2.51M 209M | EV / Sales 2021 | 17.7 x |
| Net cash position 2021 | 1.19M 1.49M 124M | Net cash position 2022 | 1.05M 1.32M 110M | EV / Sales 2022 | 24.1 x |
| P/E ratio 2021 |
7.02
x | P/E ratio 2022 |
4.77
x | Employees | 9 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 87.46% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.86% | ||
| 1 week | -1.86% | ||
| Current month | -11.12% | ||
| 1 month | -13.98% | ||
| 3 months | -36.65% | ||
| 6 months | -48.00% | ||
| Current year | -34.88% |
1 week
17.06
18.00
1 month
17.0621.50
Current year
17.0630.00
1 year
5.5743.50
3 years
5.5758.00
5 years
5.5789.85
10 years
5.57133.25
| Managers | Title | Age | Since |
|---|---|---|---|
Stephen O'Hara
FOU | Founder | 64 | 19/06/19 |
| Director of Finance/CFO | 61 | 01/12 | |
Sofia Kolyda
BRD | Director/Board Member | - | 18/14/18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Richard Davidson
CHM | Chairman | 72 | 01/18/01 |
Sean Christie
BRD | Director/Board Member | 66 | 10/18/10 |
Stephen O'Hara
FOU | Founder | 64 | 19/06/19 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/24/29 | 17.42 | -1.86% | 67 982 |
| 26/24/26 | 17.75 | 0.00% | 58,159 |
| 25/24/25 | 17.75 | 0.00% | 16,701 |
| 24/24/24 | 17.75 | 0.00% | 1,875 |
| 23/24/23 | 17.75 | 0.00% | 22,868 |
Delayed Quote London S.E., April 29, 2024 at 04:55 pm IST
More quotes
OptiBiotix Health Plc is a United Kingdom-based life sciences company. The Company is primarily engaged in identifying and developing microbial strains, compounds and formulations for use in the nutraceutical industry segment. Its technology platforms include OcptiBiome, OptiScreen and OptiBiotic. Its OptiBiome technology platform that screens identifies and/or develops microbiome modulators, which can be used in formulations to prevent, manage and a range of chronic lifestyle diseases. The OptiScreen pharmaceutical screening platform to identify microbial metabolic pathways that interact with human pathways to improve health. The OptiBiotic platform generates oligosaccharides and screens them for their ability to modulate specific microbial genera or species and their microbial end products (short chain fatty acids, such as acetate, propionate, butyrate) and physical properties (sweetness). Its products include SlimBiome, SweetBiotix, CholBiomeX3, SlimBiome Medical and WellBiome.
Calendar
26/06/2024
- Q4 2023 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -34.88% | 21.65M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +0.73% | 22.15B | |
| -17.37% | 21.02B | |
| -8.96% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- OPTI Stock
